Clinical significance of blood endocan level in breast cancer patients

Endocan expression has been associated with aggressive tumor progression and poor outcomes in various cancers. Our preclinical study demonstrated that endocan the peripheral blood potential for use as a prognostic biomarker of triple-negative breast cancer （TNBC）. Currently, clinical results collected from patients are extremely limited. Thus, this aimed to examine extent which correlates staging such patients. A total 54 confirmed who were treated at Showa University Hospital between 2020 2021 included study. Blood was obtained them, level plasma samples measured using commercial ELISA kit. The correlation clinicopathological characteristics then determined. higher staging, positivity rate luminal-type cancer, although no significant association observed. rates stages 0 I 17％ 38％, respectively. However, observed serum carcinoembryonic antigen （CEA） or 15-3 （CA15-3）, indicating could be more sensitive than frequently used markers. patient database ESM1 gene significantly any stage tissue normal tissue. This suggests is candidate new, blood-based cancer.